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Abstract
Background: Evaluation of antiretroviral treatment (ART) programmes in sub-Saharan Africa is difficult because many
patients are lost to follow-up. Outcomes in these patients are generally unknown but studies tracing patients have shown
mortality to be high. We adjusted programme-level mortality in the first year of antiretroviral treatment (ART) for excess
mortality in patients lost to follow-up.
Methods and Findings: Treatment-naı¨ve patients starting combination ART in five programmes in Coˆte d’Ivoire, Kenya,
Malawi and South Africa were eligible. Patients whose last visit was at least nine months before the closure of the database
were considered lost to follow-up. We filled missing survival times in these patients by multiple imputation, using estimates
of mortality from studies that traced patients lost to follow-up. Data were analyzed using Weibull models, adjusting for age,
sex, ART regimen, CD4 cell count, clinical stage and treatment programme. A total of 15,915 HIV-infected patients (median
CD4 cell count 110 cells/mL, median age 35 years, 68% female) were included; 1,001 (6.3%) were known to have died and
1,285 (14.3%) were lost to follow-up in the first year of ART. Crude estimates of mortality at one year ranged from 5.7% (95%
CI 4.9–6.5%) to 10.9% (9.6–12.4%) across the five programmes. Estimated mortality hazard ratios comparing patients lost to
follow-up with those remaining in care ranged from 6 to 23. Adjusted estimates based on these hazard ratios ranged from
10.2% (8.9–11.6%) to 16.9% (15.0–19.1%), with relative increases in mortality ranging from 27% to 73% across programmes.
Conclusions: Naı¨ve survival analysis ignoring excess mortality in patients lost to follow-up may greatly underestimate
overall mortality, and bias ART programme evaluations. Adjusted mortality estimates can be obtained based on excess
mortality rates in patients lost to follow-up.
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Introduction
Loss to follow-up (LTFU) is an important problem both for the
care of individual patients and the evaluation of antiretroviral
treatment (ART) programmes in low- and middle-income
countries. In a systematic review of programmes from sub-
Saharan Africa the percentage of patients lost to follow-up was
estimated to be 19%, 24% and 31% at 6 months, 12 months and
24 months of treatment, respectively [1]. Other studies have
documented an increase in LTFU in more recent years, during
which the number of patients starting ART increased steeply [2,3].
LTFU is thus becoming an increasing problem in these settings, as
programmes grow and staff-to-patient ratios decrease [4].
LTFU is also a problem for estimating outcomes at the level of
the ART programme: a meta-analysis of studies that traced patients
lost to follow-up to ascertain their vital status showed that in sub-
Saharan Africa 46% of those traced had died [5]. These deaths
generally occurred within the first months of ART, and death rates
in the first year of ART are therefore considerably higher in patients
lost to follow-up than the 7% to 13% commonly reported for ART
programmes in lower-income countries [2,6,7,8]. Standard meth-
ods of survival analysis that censor follow-up time at the last visit will
therefore underestimate overall, programme-level mortality [9].
We propose an approach based on multiple imputation [10] to
conduct sensitivity analyses adjusting estimates of cumulative
mortality during the first year of ART for the excess risk of death
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in those lost to follow-up. Our analyses are based on five large
ART programmes in sub-Saharan Africa that experienced
different levels of LTFU.
Methods
Data sources
The International epidemiological Database to Evaluate AIDS
(IeDEA) is a network of HIV/AIDS treatment programmes in
Africa, North and South America and Asia. The collaboration has
been described in detail elsewhere [5,11,12]. For the present
analysis we used data from five treatment programmes in sub-
Saharan Africa: the Centre de Prise en Charge de Recherches et
de Formation (CePReF) from Abidjan, Coˆte d’Ivoire [8] (West
African IeDEA Region); the Academic Model for the Prevention
and Treatment of HIV/AIDS (AMPATH) from Eldoret, Kenya
[13]] (East African IeDEA Region); the Lighthouse clinic in
Lilongwe, Malawi [14] (Southern African IeDEA Region); and the
township programmes in Khayelitsha [15] and Gugulethu [16],
both in Cape Town, South Africa (Southern African IeDEA
Region).
Inclusion criteria and definitions
All treatment-naı¨ve patients starting ART with documented
age, sex, CD4 count and clinical stage at the start of treatment
(baseline) and with at least one day of follow-up were included.
ART was defined as any combination of three or more
antiretroviral drugs. Follow-up time was measured from the start
of ART and censored at the earliest of the date of death, the date
of the last follow-up visit, or 12 months after starting ART.
Patients were considered lost to follow-up if their last visit preceded
the closure date of the database by nine months or more and no
death had been recorded by that time. Nine months was obtained
by adding three months (within which patients could have
returned) to the maximum interval of six months between
scheduled visits. Calculations of LTFU rates were therefore based
on patients who started ART at least nine months before the
closure date of the database. The outcome of interest was mortality
from all causes in the first year of ART. We used an intention-to-
continue treatment approach, ignoring changes to treatment,
treatment interruptions and terminations.
Estimation of mortality in patients lost to follow-up
To account for the excess risk of death in patients lost to follow-
up we estimated, for each ART programme, a constant mortality
hazard ratio comparing patients lost to follow-up with those not
lost to follow-up. Henceforth, we refer to these hazard ratios as
HRLTFU. Estimates were based on a meta-regression analysis of
studies tracing patients lost to follow-up in sub-Saharan Africa that
found a negative relationship between the overall rate of LTFU
and mortality in patients lost to follow-up: mortality at one year
among patients lost to follow-up declined from around 60% to
20% as LTFU increased from 5% to 50% [5]. We used the
regression equation to estimate the one-year mortality risk among
patients lost to follow-up that is predicted by the rate of LTFU in
that programme. We then identified the HRLTFU for each
programme that produced estimated cumulative mortality at one
year consistent with the predicted mortality among patients lost to
follow-up. In a second step we conducted sensitivity analyses
including a range of assumed HRLTFU. We chose a range of
HRLTFU between 1 (no informative censoring) and 40. This range
is justified by the very high mortality that has been observed in
some ART programmes among patients lost to follow-up [5].
Multiple imputation of survival times
We treated LTFU as a missing data problem, and used multiple
imputation [10] to fill in the missing survival times in patients lost
to follow-up and hence to obtain estimates of one-year mortality
that were adjusted for LTFU. Imputation of missing survival times
was based on a pattern-mixture modelling approach, in which we
stratify subjects by their pattern of missing values, in our case
LTFU status, and formulate distinct imputation models for each
stratum [17]. For patients retained in care we fitted a proportional
hazards Weibull model using the original right-censored data. The
mode included baseline covariates age (16–29; 30–39; 40–49; $50
years), gender, type of ART regimen (non nucleoside reverse
transcriptase inhibitor (NNRTI)-based; protease inhibitor (PI)-
based: other or unknown), baseline CD4 count (,25; 25–49; 50–
99; 100–199; $200 cells/mL), clinical stage of disease (less
advanced = WHO stage 1 or 2; advanced = WHO stage 3 or 4),
and indicators for the treatment programme. Imputation of
survival times in patients lost to follow-up was based on the same
model but assumed that the hazard of death was increased by
factor HRLTFU. The multiple imputation procedure consisted of
four steps:
1) Fit a Weibull survival model to the original censored survival
data.
2) Specify a value of HRLTFU. Randomly sample the time from
LTFU to death in each patient lost to follow-up, based on
the model fitted in step 1, with the hazard of death increased
by factor HRLTFU. Censor follow-up at one year, if imputed
survival extends to beyond one year.
3) Repeat this procedure 10 times, to create 10 datasets
including imputed survival times for patients lost to follow-
up.
4) Estimate mortality at one year for each of the 10 datasets
and combine estimates using Rubin’s rules [18] to obtain
overall estimates of mortality at one year adjusted for bias
due to LTFU.
Further technical details of this approach are given in the
Appendix S1.
Analysis of heterogeneity between programmes
Differences in cumulative mortality between programmes will
be partly due to differences in the distribution of patient
characteristics at baseline. We therefore also estimated cumulative
mortality for a ‘‘typical patient group’’ whose baseline character-
istics correspond to the most frequent category for each
characteristic, i.e. female, age 30 to 39 years, NNRTI-based
regimen, CD4 100 to 199 cells/mL, and advanced stage of disease
(WHO stage 3 or 4). Finally, we compared coefficients of variation
to investigate whether adjusting for predicted mortality in patients
lost to follow-up reduced between-programme heterogeneity. All
analyses were done using Stata version 10.1 (Stata Corporation,
College Station, Texas, USA).
Results
The five treatment programmes provided data on 15,915
patients, of whom 10,773 (68%) were women. Median age was 35
years (inter-quartile range [IQR] 29–41 years) and the median
CD4 cell count at the start of ART was 110 cells/mL (IQR 45–
182) (Table 1). A total of 1,001 deaths (6.3% of patients) were
recorded during 10,265 person-years of follow-up and 1,285
(14.3%) patients were lost to follow-up in the first year of ART.
Mortality in ART Programmes
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This percentage ranged from 5.7% to 28.9% across the five
treatment programmes.
Table 2 compares baseline CD4 count and disease stage in
patients who were not lost to follow-up, patients who were known
to have died and patients who were lost to follow-up in the first
year of ART. Patients who died had lower median CD4 counts
and more advanced disease at baseline, compared to the other two
groups, in each of the treatment programmes. In patients lost to
follow-up, the median baseline CD4 count and prevalence of
advanced disease were intermediate between the patients who died
and those not lost to follow-up. These patterns were similar across
treatment programmes, with the exception that patients lost to
follow-up had somewhat higher baseline CD4 counts in
Gugulethu and the prevalence of advanced disease was slightly
lower in patients lost to follow-up in Gugulethu and Lighthouse,
compared with patients not lost to follow-up.
The crude estimates of cumulative mortality at one year (based
on the original data with censoring of follow-up time in patients
lost to follow-up), were 8.6% (95% CI 7.5–9.9%) in CePReF,
5.7% (4.9–6.5%) in AMPATH, 10.9% (9.6–12.4%) in Lighthouse,
9.6% (8.2–11.2%) in Gugulethu, and 9.3% (8.4–10.4%) in
Khayelitsha. As expected, estimates from imputation models were
similar when the assumed HRLTFU was 1 (and therefore the
censoring of follow-up time non-informative): 8.6% (7.5–9.8%) for
CePReF, 5.9% (5.1–6.9%) for AMPATH, 10.8% (9.4–12.3%) for
Lighthouse, 9.1% (7.7–10.7%) for Gugulethu and 9.3% (8.3–
10.4%) for Khayelitsha (Table 3). In the typical patient group,
assuming HRLTFU = 1, estimated one-year mortality varied
between 4.2% (3.4–5.2%) and 7.3% (6.0–8.9%) in the different
programmes.
The meta-regression analysis suggested that for each 10%
increase in the programme LTFU rate, the odds of deaths among
patients lost to follow-up was multiplied by 0.67 [5]. Table 3 shows
the mortality among patients lost to follow-up for each programme
as predicted from the rate of LTFU in that programme, and the
values of HRLTFU that correspond to the predicted mortality. The
lowest predicted HRLTFU were 6 and 12, for Lighthouse and
AMPATH respectively: these were the programmes with the
highest LTFU rates (Table 1). The predicted HRLTFU for the
remaining three programmes, which had substantially lower rates
of LTFU, ranged between 18 and 23. For the HRLTFU
corresponding to the predicted mortality in patients lost to
follow-up, the adjusted mortality in all patients ranged from
10.2% (95% CI 8.9–11.6%) in AMPATH to 16.9% (15.0–19.1%)
in Lighthouse. The corresponding range for adjusted mortality in
the typical patient group was 6.7% (5.6–8.0%) to 10.8% (8.8–
13.2%). The relative increase in mortality, compared to mortality
when HRLTFU = 1, varied from 27% to 73% overall, and from
26% to 67% in the typical patient group. The highest relative
increases in mortality were observed for Lighthouse and
AMPATH; the programmes with the highest rate of LTFU
(Table 1).
Table 1. Characteristics of patients enrolled in different treatment programmes.
Treatment
programme Country
No eligible
patients
No (%)
women
Median age
(IQR)
Person-years of
follow-up in first
year
No (%) deaths
in first year
No (% of eligible#) lost
to follow-up in first year
CePReF Coˆte d’Ivoire 2518 1846 (73) 35 (30–42) 2010 189 (7.5) 269 (12.6)
AMPATH Kenya 5491 3716 (68) 36 (30–43) 2580 181 (3.3) 333 (22.0)
Lighthouse Malawi 2754 1647 (60) 36 (30–43) 1550 204 (7.4) 439 (28.9)
Gugulethu South Africa 1872 1272 (68) 33 (29–39) 1247 137 (7.3) 87 (8.3)
Khayelitsha South Africa 3280 2292 (70) 32 (28–38) 2878 290 (8.8) 157 (5.7)
Overall 15915 10773 (68) 35 (29–41) 10265 1001 (6.3) 1285 (14.3)
IQR, interquartile range. CePReF, Centre de Prise en Charge de Recherches et de Formation. AMPATH, Academic Model for the Prevention and Treatment of HIV/AIDS.
#Excluding patients with unknown follow-up status (not known to have died and a last visit date in the first year, but with less than nine months of additional follow-up
until the closure date of the cohort).
doi:10.1371/journal.pone.0014149.t001
Table 2. Clinical characteristics at baseline of patients known to survive or die in the first year of antitretroviral therapy and
patients lost to follow-up in the first year of therapy.
Median CD4 count (IQR; cells/mL) Percent with advanced disease (95% CI*)
Treatment
programme
Not lost, not dead
in first year
Not lost, dead
in first year
Lost to follow-up
in first year
Not lost, not
dead in first year
Not lost, dead
in first year
Lost to follow-up
in first year
CePReF 142 (64–223) 52 (13–136) 108 (29–198) 80% (78–82) 96% (93–98) 83% (78–88)
AMPATH 118 (48–193) 52 (11–122) 73 (20–165) 55% (53–56) 86% (80–91) 65% (59–70)
Lighthouse 140 (67–223) 52 (18–124) 93 (38–177) 86% (84–88) 95% (91–97) 82% (78–86)
Gugulethu 107 (56–162) 53 (16–111) 115 (48–177) 79% (77–81) 95% (90–98) 78% (68–86)
Khayelitsha 93 (41–149) 37 (13–97) 64 (29–120) 89% (88–90) 98% (96–99) 92% (86–96)
Overall 116 (51–186) 48 (14–115) 90 (29–170) 74% (73–75) 94% (93–96) 79% (76–81)
IQR, interquartile range. CePReF, Centre de Prise en Charge de Recherches et de Formation. AMPATH, Academic Model for the Prevention and Treatment of HIV/AIDS.
*Binomial exact confidence interval.
doi:10.1371/journal.pone.0014149.t002
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Figure 1 shows the increases in overall and programme-specific
estimated mortality at one year with increasing HRLTFU in the
typical patient group. For example, as the assumed HRLTFU
increased, mortality in the AMPATH programme changed from
the lowest mortality to being close to the average estimate across
programmes. In contrast, mortality in Lighthouse was higher than
in the other programmes, regardless of the assumed HRLTFU.
Variation in slopes between treatment programmes reflects
differences in the proportion of patients lost to follow-up, the
observed follow-up time for patients lost to follow-up, as well
variation in covariates between treatment programmes. The shape
of the curve reflects the use of proportional hazards in the Weibull
models (see Appendix S1).
Table S1 gives estimates of mortality at one year with 95% CI
in the typical patient group for different HRLTFU separately for
each programme and overall. When assuming that mortality rates
in patients lost to follow-up were twice those in patients not lost to
follow-up (HRLTFU = 2), overall mortality in the typical patient
group increased from 5.8% to 6.1% (5.2%–7.2%). Overall
mortality further increased to 7.9% (6.7%–9.4%), 9.4% (8.0%–
11.1%) and 11.0% (9.7%–12.4%) for HRLTFU of 10, 20 and 40,
respectively. Finally, adjusting for predicted mortality in patients
lost to follow-up did not explain the between-programme
variability in mortality: for the typical patient group, the
coefficients of variation were 0.18 before adjustment for mortality
in patients lost to follow-up and 0.19 after adjustment. The
coefficients of variation for all patients were 0.18 and 0.17,
respectively.
Discussion
Mortality among patients lost to follow-up in ART treatment
programmes in sub-Saharan Africa is high so that deaths reported
for patients who remain in care may seriously underestimate
mortality among all patients starting ART in a given programme
[5]. By formulating this problem in terms of missing data we
obtained adjusted mortality estimates, based on assumed hazard
ratios for excess mortality in patients lost to follow-up. These
sensitivity analyses are useful to estimate mortality among all
patients starting ART, and to adjust prognostic models for bias
due to informative censoring. Based on plausible estimates for
excess mortality in patients lost to follow-up, programme-level
mortality was increased by 27% to 73% overall, and 26% to 67%
in patients with typical characteristics at the start of ART, with
greater increases in programmes with higher rates of LTFU.
Differences in rates of LTFU did not, however, explain variability
in programme-specific mortality, even after accounting for patient
characteristics at the start of ART.
Several ART programmes have recently traced patients lost to
follow-up and used information on their vital status to derive
adjusted mortality estimates. For example, in a cohort study of
410 patients in Gaborone (Botswana), the vital status of 46
(67.6%) of 68 patients lost to follow-up could be ascertained.
Table 3. Cumulative mortality (95% CI) at one year after starting ART for HRLTFU = 1 and for HRLTFU corresponding to the predicted
percentage mortality among patients lost to follow-up for each programme.
Treatment
programme
Predicted
mortality
(%) among
LTFU*
Value of HRLTFU
corresponding
to predicted
mortality in LTFU Mortality in all patients (%) Mortality (%) in typical patient group
When
HRLTFU =1
Corresponding to
predicted HRLTFU
Relative
increase
When
HRLTFU =1
Corresponding to
predicted HRLTFU
Relative
increase
CePReF 51% 18 8.6 (7.5–9.8) 13.8 (12.4–15.4) 60% 6.2 (5.1–7.6) 10.1 (8.2–12.3) 63%
AMPATH 42% 12 5.9 (5.1–6.9) 10.2 (8.9–11.6) 73% 4.2 (3.4–5.2) 7.0 (5.7–8.6) 67%
Lighthouse 35% 6 10.8 (9.4–12.3) 16.9 (15.0–19.1) 56% 7.3 (6.0–8.9) 10.8 (8.8–13.2) 48%
Gugulethu 56% 23 9.1 (7.7–10.7) 12.2 (10.5–14.3) 34% 6.4 (5.1–7.9) 8.6 (7.0–10.5) 34%
Khayelitsha 58% 20 9.3 (8.3–10.4) 11.8 (10.7–13.0) 27% 5.3 (4.4–6.4) 6.7 (5.6–8.0) 26%
CePReF, Centre de Prise en Charge de Recherches et de Formation. AMPATH, Academic Model for the Prevention and Treatment of HIV/AIDS.
Estimates for the typical patient group were from Weibull models while estimates for programme-specific mortality were from Kaplan-Meier methods. The typical
patient group had baseline characteristics age 30 to 39; female; NNRTI-based regimen; CD4 count 100 to 199 cells/mL; advanced stage of disease (WHO stage 3 or stage
4).
*Predicted from a meta-regression analysis of the relationship between mortality in patients lost to follow-up and the programme LTFU rate [5].
doi:10.1371/journal.pone.0014149.t003
Figure 1. Relationship between assumed HRLTFU and estimated
mortality following outcome imputation in a typical patient
group. The circles indicate the expected mortality in the typical patient
group for the value of HRLTFU corresponding to predicted mortality in
patients lost to follow-up. CePReF, Centre de Prise en Charge de
Recherches et de Formation. AMPATH, Academic Model for the
Prevention and Treatment of HIV/AIDS.
doi:10.1371/journal.pone.0014149.g001
Mortality in ART Programmes
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Mortality increased from 7.1% before to 16.8% after tracing
patients [19]. Geng and colleagues [20] traced a sample of 128
patients out of 829 patients lost to follow-up in Mbarara
(Uganda), and obtained the vital status of 111 (87%) patients.
Assuming that the latter were representative for all patients lost to
follow-up, the authors used weighted Kaplan-Meier curves to
obtain adjusted estimates: one-year mortality was 7.5%, com-
pared to 1.7% before adjustment. Yiannoutsos and colleagues
traced 1143 out of 3528 patients lost to follow-up in the
Academic Model for the Prevention and Treatment of HIV/
AIDS (AMPATH) programme in Eldoret (Kenya), and ascer-
tained the vital status of 522 (54%) of those traced [21]. Using a
double-sampling approach [22] the adjusted mortality estimate
at one year was 10.7%, a six-fold increase compared to the
unadjusted estimate [21].
The AMPATH programme was also included in our analysis:
we found a mortality estimate at one year of 10.2%, similar to the
double-sampling study [21], when we used the estimate for excess
mortality in patients lost to follow-up from the meta-regression
model [5]. In comparison the crude estimate (based on the original
data with censoring of follow-up in patients lost to follow-up) for
AMPATH was 5.7%. The double-sampling study in AMPATH
thus validates our approach, indicating that in this programme the
mortality rate in patients lost to follow-up is about 12 times greater
than in patients not lost to follow-up (HRLTFU = 12).
Several mechanisms might contribute to the higher mortality in
patients lost to follow-up. First, patients might not return to the
clinic because they have died. This is supported by the fact that
patients with less favourable risk factor profiles at baseline (worse
prognosis) are more likely to be lost to follow-up. Other possible
reasons include incomplete adherence to ART [23], economic
difficulties related to costs of transport and care [3,24,25], and
HIV-related stigma [9,24,26]. The interruption or discontinuation
of ART might then have led to disease progression and death. The
limited evidence that is available indicates, however, that most
deaths occurred shortly after the last clinic visit [5,27], and are
therefore probably related to opportunistic infections present at
baseline. Deaths soon after starting ART are therefore likely to
explain a large proportion of the excess mortality in patients lost to
follow-up [28,29]. In industrialized settings LTFU may have
opposite effects if patients who feel well are more likely to leave the
study than sick patients. For example, a French study found that
patients with higher CD4 cell counts at baseline were more likely
to be lost to follow-up [30]. Patients who returned to care after
LTFU, however, experienced higher mortality than patients who
attended clinics regularly [31].
Our approach has several strengths and limitations. It provides
programme-specific estimates of mortality that are adjusted for
differences in mortality rates between patients lost to follow-up and
patients not lost to follow-up. Adjusted mortality can be computed
for the whole population or for a particular covariate reference
group. The latter facilitates comparison of adjusted mortality
across different programmes, and avoids problems that occur
when adjusting survival curves for confounders [32]. In contrast to
linear regression, the use of centred covariates in survival analysis
does not produce an estimate of average survival [32]. For this
reason, we reported estimates of cumulative mortality for a group
of patients with typical covariate values, adjusted for a range of
assumed LTFU hazard ratios.
Deaths among patients lost to follow-up can be ascertained by
tracing patients not returning to the clinic. Bias may thus be
reduced or even abolished, but vital status often remains unknown
in a substantial proportion of patients lost to follow-up, despite
considerable efforts to trace them, and patients traced may
therefore not be representative of all patients lost to follow-up [5].
Sensitivity analyses assuming different excess mortality ratios are
useful in this situation, allowing the estimation of programme-level
mortality for a range of plausible ratios.
With a cut-off of nine months our definition of LTFU was
conservative and minimized the number of patients incorrectly
classified as LTFU, i.e. the number of false positives. We will,
however, have misclassified some patients as still being in care who
were in fact lost to follow-up. A less conservative cut-off of six
months would have increased the overall percentage of patients
LTFU from 14.3% to 17.7%. Chi and colleagues recently
examined the sensitivity and specificity of different definitions of
LTFU in a large ART programme in Lusaka, Zambia [33]. They
categorized LTFU on the basis of the number of days late for a
scheduled visit, and determined the proportion of persons who
returned to care within the subsequent year. Chi and colleagues
found that for a cut-off of greater than 6 months, the sensitivity
was 65.8% and the specificity 99.0% [33].
A limitation of our study is that we were not able to distinguish
between LTFU and transfer of patients to another ART clinic:
transfers out were not consistently recorded. Also, patients may
self-transfer to another clinic without notifying the clinic where
ART was initiated. Studies that traced patients lost to follow-up
and documented reasons for LTFU indicate that such ‘silent’
transfers had occurred in 8% [25], 9% [24], 17% [34] and 19%
[35] of patients. Transfer out may or may not be associated with
increased or reduced mortality. For example if patients transfer
entirely for practical reasons, for example to a clinic closer to their
homes, then increased or reduced mortality is unlikely. Converse-
ly, if patients are transferred for clinical reasons, for example to a
higher or lower level of care, mortality is likely to differ. We now
record transfers out and reasons for transfers systematically in
IeDEA, allowing the imputation of survival times separately for
patients lost to follow-up and patients transferred out in future
analyses.
In conclusion, patients lost to follow-up in ART programmes in
sub-Saharan Africa are at a substantially higher risk of death than
patients who remain in care. LTFU in treatment programmes in
sub-Saharan Africa is often substantial [1,3] and therefore
standard methods of survival analysis that censor patients at the
time they are lost to follow-up may greatly underestimate overall
mortality and bias programme evaluations. Therefore, sensitivity
analyses adjusting mortality rates for plausible rates of excess
mortality among patients lost to follow-up should be used in
programme evaluations and in prognostic models. Future
research should focus on ways to reduce LTFU, as well as on
identifying factors responsible for the high risk of death in patients
who do not remain in care, including undiagnosed opportunistic
infections and cancers. A better understanding of these factors
will contribute both to improve patient care and programme
evaluation.
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